HITIQ (ASX: HIQ) Announces Research Partnership with Monash University
HITIQ Limited (ASX: HIQ) has announced a significant research partnership with Monash University, placing its PROTEQT technology at the core of a $799,866 Australian Research Council (ARC) Discovery Project grant. This investor update highlights an agreement that delivers immediate commercial value through a $200,000 pre-committed revenue stream and establishes crucial clinical evidence for the company’s expansion in the HITIQ brain injury research sector.
The collaboration signifies growing institutional recognition of HITIQ’s capabilities. Monash University selected PROTEQT as its preferred instrumented mouthguard platform after a rigorous evaluation, underscoring the technology’s performance in providing high-fidelity head impact data.
Executive Chair of HITIQ, Earl Eddings, commented on the development: “This partnership validates our technology’s scientific capabilities and positions HITIQ at the forefront of research that will shape global understanding of head impact exposure and brain injury risk.”
What is the financial scope of the Monash University partnership?
The agreement with Monash University provides both immediate revenue and long-term strategic value. It positions HITIQ’s technology at the centre of a prestigious research programme focused on concussion management.
Key Financial Details:
- Confirmed Revenue: $200,000 from the sale of 400 PROTEQT units, with delivery scheduled for January 2026.
- Total Grant Funding: The research is supported by a $799,866 ARC Discovery Project grant.
- Secured Purchase: The $200,000 purchase is a pre-committed agreement secured within the university’s project budget allocation.
This structure allows HITIQ to generate revenue whilst concurrently building the clinical evidence base required for broader regulatory and market acceptance. The university has formally confirmed the selection, with ARC funds anticipated to be available in January 2026 for the finalisation of contractual arrangements.
How does PROTEQT technology advance HITIQ brain injury research?
PROTEQT technology is designed to address critical gaps in sports medicine by providing objective, quantifiable measurements of head impacts in real-time. This capability is essential for correlating physical events with the biological markers of brain injury, moving beyond subjective symptom reporting.
Technical Capabilities:
- Provides real-time biomechanical head impact data collection with high-fidelity precision.
- Integrates with advanced computational models to analyse brain strain.
- Enables cumulative impact exposure analysis for assessing long-term injury risk.
By providing this level of data, the technology supports the development of evidence-based safety protocols and guidelines. This creates a competitive advantage and positions HITIQ as a preferred partner for leading research institutions conducting HITIQ brain injury research.
Why is the ARC Discovery Project grant significant?
The ARC Discovery Project grant is part of Australia’s most competitive research funding programme, awarded following intensive international peer review. This validation has considerable implications for HITIQ’s commercial and regulatory pathways.
The research programme, titled “Combining biomechanics and biomarkers to establish brain injury thresholds,” will integrate PROTEQT’s data with advanced biomarker analysis. This is expected to create a highly comprehensive dataset for understanding brain injury risk from cumulative head impacts.
| Research Programme Details | Information |
|---|---|
| Total ARC Grant Funding | $799,866 over the project’s duration |
| PROTEQT Units Required | 400 units for a comprehensive study |
| Research Focus | Combining biomechanics and biomarkers |
| Expected Equipment Delivery | January 2026 |
Chief Investigator at Monash University, Dr Stuart McDonald, stated: “By combining high-fidelity PROTEQT head impact data with advanced computational models of brain strain and highly sensitive blood-based markers of brain injury, we aim to move beyond simple acceleration cut-offs towards biologically grounded thresholds.”
What does this partnership mean for HITIQ’s market position?
Monash University’s selection of HITIQ technology reinforces the company’s established track record. Monash, a top 50 global university, has a history of collaboration with HITIQ on previous studies, providing a foundation for this expanded partnership.
The agreement is a successful execution of HITIQ’s strategy to generate revenue while building long-term competitive advantages through clinical validation. This dual-benefit model strengthens the company’s position in the HITIQ brain injury research field and provides a template for future collaborations with other leading institutions globally.
For investors, this ASX announcement confirms a clear revenue pipeline and a strategic pathway toward wider market adoption, supported by credible, independent academic validation.
Want more ASX news?
Looking to stay ahead of significant announcements in the ASX technology sector? Join over 20,000 investors who receive StockWire X’s Big News Blasts—a free email service delivering major company news, including detailed analysis, directly to subscribers’ inboxes. This quality-filtered service focuses exclusively on significant market-moving updates from non-resource ASX companies in technology, biotechnology, healthcare, finance, and industrials. Subscribe today to ensure you never miss critical developments that could impact your investment decisions.